疾病
格列本脲
糖尿病
神经保护
医学
认知障碍
认知
药品
人口
加兰他明
发病机制
生物信息学
精神科
药理学
痴呆
内科学
生物
内分泌学
多奈哌齐
环境卫生
作者
Alexander Zubov,Zamira M. Muruzheva,Maria S. Tikhomirova,Marina N. Karpenko
标识
DOI:10.1080/13813455.2020.1789170
摘要
In the view of progressively aging human population and increased occurrence of dysmetabolic disorders, such as diabetes mellitus, cognitive impairment becomes a major threat to the national health. To date, the molecular mechanisms of cognitive dysfunction are partially described for diabetes and diseases of different nature, such as Alzheimer disease or Parkinson disease. The emergence of data pointing towards pleotropic effects of hypoglycaemic medicines indicates involvement of their targets in pathogenesis of cognitive impairment. We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship of its targets to the pathogenesis of cognitive impairment.
科研通智能强力驱动
Strongly Powered by AbleSci AI